It is the world’s first innovation drug in the field of stroke that has received US FDA BTD. Sanbexin® sublingual tablet is a dual-target brain cytoprotective agent composed of edaravone and dexborneol. These two active ingredients exert synergistic anti-oxidant and anti-inflammatory effects, which can significantly reduce brain cell damage caused by acute ischemic stroke.

Sublingual tablet is designed for quick disintegration under the tongue. This facilitates the active ingredients' rapid absorption into the blood and brain, bypasses the first-pass hepatic metabolism, which is conducive to higher drug bioavailability and faster onset of action. Sanbexin injections and sublingual tablets forms a combination that enables patients to receive a complete course of brain cytoprotection in and outside of the hospital during the acute phase of stroke.